Cargando…
Hepatocyte growth factor and soluble cMet levels in plasma are prognostic biomarkers of mortality in patients with severe acute kidney injury
BACKGROUND: Hepatocyte growth factor (HGF)/cMet pathway is necessary for repair and regeneration following acute kidney injury (AKI). We evaluated the clinical potential of plasma HGF and soluble cMet as prognostic biomarkers for severe AKI requiring continuous renal replacement therapy (CRRT). METH...
Autores principales: | Li, Lilin, An, Jung Nam, Lee, Jeonghwan, Shin, Dong Jin, Zhu, Shi Mao, Kim, Jin Hyuk, Kim, Dong Ki, Ryu, Dong-Ryeol, Kim, Sejoong, Lee, Jung Pyo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Nephrology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685369/ https://www.ncbi.nlm.nih.gov/pubmed/34510856 http://dx.doi.org/10.23876/j.krcp.20.258 |
Ejemplares similares
-
Urinary cMet as a prognostic marker in immunoglobulin A nephropathy
por: An, Jung Nam, et al.
Publicado: (2020) -
cMet agonistic antibody attenuates apoptosis in ischaemia‐reperfusion–induced kidney injury
por: An, Jung Nam, et al.
Publicado: (2020) -
Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
por: Kim, Yong Chul, et al.
Publicado: (2018) -
Renoprotective effects of a novel cMet agonistic antibody on kidney fibrosis
por: Kim, Yong Chul, et al.
Publicado: (2019) -
Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
por: Kim, Ki-Hyun, et al.
Publicado: (2017)